Europe
Companies strengthen their leadership teams and executive boards with this week’s Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A late-stage lung cancer drug under development by OSE Immunotherapeutics met its 12-month primary endpoint for survival rates following a Step-1 analysis.
Under terms of the deal, Aurobindo would pay $900 million upfront with an additional $100 million in milestone payments. However, in a filing with the Securities and Exchange Commission, the company announced it had terminated that agreement.
Biopharma companies from across the globe provide updates on their pipelines and business practices.
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
In a statement, the FDA said “objectionable conditions were found and documented” but did not meet the threshold for regulatory action against the Swiss pharma giant.
Secarna’s approach efficiently targets IDO1 and TDO2, key enzymes that degrade the essential amino acid tryptophan into immunosuppressive kynurenine
Under terms of the agreement, Charles River Laboratories will be able to provide its clients with the use of Deciphex’s flagship product.
The following is a roundup of some of this week’s non-coronavirus biopharma news.
PRESS RELEASES